Bg pattern

ZOLMITRIPTAN FLAS CINFA 2.5 mg ORALLY DISINTEGRATING TABLETS

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use ZOLMITRIPTAN FLAS CINFA 2.5 mg ORALLY DISINTEGRATING TABLETS

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Zolmitriptan Flas Cinfa2.5 mg orodispersible tablets EFG

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Zolmitriptan Flas Cinfa and what is it used for
  2. What you need to know before you take Zolmitriptan Flas Cinfa
  3. How to take Zolmitriptan Flas Cinfa
  4. Possible side effects
  5. Storage of Zolmitriptan Flas Cinfa
  6. Contents of the pack and other information

1. What is Zolmitriptan Flas Cinfa and what is it used for

Zolmitriptan Flas Cinfa contains zolmitriptan and belongs to a group of medicines called triptans.

Zolmitriptan Flas Cinfa is used to treat migraine headaches in adults over 18 years of age.

  • Migraine symptoms may be caused by the dilation of blood vessels in the head. It is believed that Zolmitriptan Flas Cinfa decreases the dilation of these blood vessels. This helps to relieve the headache and other symptoms of a migraine attack, such as feeling sick (nausea or vomiting) and sensitivity to light and sound.
  • Zolmitriptan Flas only works when a migraine attack has already started. It will not prevent you from having a migraine attack.
Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you take Zolmitriptan Flas Cinfa

Do not take Zolmitriptan Flas Cinfa

  • If you are allergic to zolmitriptan or any of the other ingredients of this medicine (listed in section 6).
  • If you have high blood pressure.
  • If you have ever had heart problems, including a heart attack, angina (chest pain caused by exercise or effort), Prinzmetal's angina (chest pain that occurs at rest), or have experienced heart-related symptoms such as shortness of breath or pressure on the chest.
  • If you have had a stroke (cerebrovascular accident) or symptoms of short duration similar to a stroke (transient ischemic attack or TIA).
  • If you have severe kidney problems.
  • If you are taking other medicines for migraine (such as ergotamine or ergot-type medicines like dihydroergotamine and methysergide) or other migraine medicines from the triptan group. For more information, see the section "Other medicines and Zolmitriptan Flas Cinfa".

If you are not sure if any of the above applies to you, consult your doctor or pharmacist.

Warnings and precautions

Consult your doctor or pharmacist before starting to take Zolmitriptan Flas Cinfa:

  • If you are at risk of suffering from ischemic heart disease (poor blood flow in the heart arteries). The risk is greater if you smoke, have high blood pressure, high cholesterol levels, diabetes, or if a family member has ischemic heart disease.
  • If you have been told you have Wolff-Parkinson-White syndrome (a type of abnormal heartbeat).
  • If you have ever had liver problems.
  • If you suffer from headaches other than your usual migraine headaches.
  • If you are taking any other medicine for the treatment of depression (see the section "Other medicines and Zolmitriptan Flas Cinfa").

If you go to the hospital, inform the medical staff that you are taking Zolmitriptan Flas Cinfa.

Zolmitriptan Flas is not recommended for people under 18 or over 65 years of age.

As with other migraine treatments, excessive use of Zolmitriptan Flas may cause you to have daily headaches or worsen your migraine headaches. Consult your doctor if you think this is the case. You may need to stop using Zolmitriptan Flas to correct the problem.

Other medicines and Zolmitriptan Flas Cinfa

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This includes herbal medicines and medicines you buy without a prescription.

In particular, tell your doctor if you are taking any of the following medicines:

Migraine medicines

  • If you take other triptans different from zolmitriptan: wait 24 hours before taking Zolmitriptan Flas.
  • After taking Zolmitriptan Flas Cinfa, wait 24 hours before taking other triptans different from Zolmitriptan Flas Cinfa.
  • If you take medicines that contain ergotamine or ergot-type medicines (such as dihydroergotamine or methysergide), wait 24 hours before taking Zolmitriptan Flas Cinfa.
  • After taking Zolmitriptan Flas Cinfa, wait 6 hours before taking ergotamine or ergot-type medicines.

Medicines for depression

  • Moclobemide or fluvoxamine.
  • Medicines called SSRIs (selective serotonin reuptake inhibitors).
  • Medicines called SNRIs (serotonin and norepinephrine reuptake inhibitors) such as venlafaxine, duloxetine.

Other medicines

  • Cimetidine (for indigestion or stomach ulcers).
  • An antibiotic from the quinolone group (such as ciprofloxacin).

If you are using herbal preparations that contain St. John's Wort (Hypericum perforatum), you may be more likely to experience side effects from Zolmitriptan Flas.

Taking Zolmitriptan Flas Cinfa with food and drinks

You can take Zolmitriptan Flas with or without food. This does not affect how Zolmitriptan Flas works.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, consult your doctor or pharmacist before using this medicine.

  • The use of Zolmitriptan Flas during pregnancy is not recommended. Before taking Zolmitriptan Flas Cinfa, inform your doctor if you are pregnant or trying to become pregnant.
  • Avoid breastfeeding for 24 hours after taking zolmitriptan.

Driving and using machines

This medicine, like migraine, can cause drowsiness. If you experience these effects, avoid driving or using machines, as it may be dangerous.

During a migraine attack, your reactions may be slower than usual. Keep this in mind when driving or using tools or machines.

Zolmitriptan Flas Cinfa contains aspartame

This medicine contains 0.9 mg of aspartame in each tablet.

Aspartame is a source of phenylalanine, which may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine accumulates because the body cannot eliminate it properly.

3. How to take Zolmitriptan Flas Cinfa

Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.

You can take Zolmitriptan Flas as soon as a migraine headache starts. You can also take it once the attack has started.

  • The recommended dose is one tablet.
  • You can take another tablet after 2 hours if the migraine still persists or if it recurs within 24 hours.

If the tablets do not provide sufficient relief for your migraine, inform your doctor. Your doctor may increase the dose to 5 mg or change your treatment.

Do not use more than the prescribed dose.

  • Do not use more than two doses in a day. The maximum daily dose is 5 mg.

Take the orodispersible tablet as follows:

  1. Do not crush the orodispersible tablet

To avoid crushing the orodispersible tablet, do not press the blister (Figure 1).

Hand holding a syringe with a needle going through the skin and muscle, showing incorrect injection angle with a red cross

  1. Separate a blister

Each blister pack contains six blisters, which are separated by perforations. Separate a blister by following the perforated lines (Figure 2).

Two hands holding a rectangular transparent medicinal patch with rounded edges on the skin

  1. Remove the foil

Remove the foil carefully, starting from the corner where it says "peel off aluminum" (Figures 3 and 4).

Hypodermic needle with bevel up inserted into a transparent cylindrical container

Needle injecting into the skin at an upward angle with an arrow indicating the direction of injection

  1. Remove the orodispersible tablet

Remove the orodispersible tablet with dry hands and place it on your tongue, where it will dissolve and be swallowed with saliva. You do not need to drink water to swallow your tablet (Figure 5).

Hand holding a syringe with a needle inserted into the skin at an angle, showing subcutaneous injection technique figure 5

If you take more Zolmitriptan Flas Cinfa than you should

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount ingested.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Some of the symptoms mentioned below may be part of the migraine attack itself.

Stop taking Zolmitriptan Flas Cinfa and contact your doctor immediately if you experience any of the following side effects:

Rare side effects (may affect up to 1 in 1,000 people):

  • Allergic reactions/hypersensitivity, including rash and swelling of the face, lips, mouth, tongue, or throat; difficulty swallowing or breathing difficulties.

Very rare side effects (may affect up to 1 in 10,000 people):

  • Angina (chest pain, often caused by exercise), heart attack, or spasm of the heart blood vessels. You may notice chest pain or shortness of breath.
  • Spasm of the intestine blood vessels that can damage your intestine. You may notice stomach pain or bloody diarrhea.

Other side effects that may occur:

Common side effects (may affect up to 1 in 10 people):

  • Abnormal sensations such as tingling in the fingers of the hands and feet or sensitive skin to touch.
  • Feeling of drowsiness, dizziness, or warmth.
  • Headache.
  • Irregular heartbeat.
  • Nausea. Vomiting.
  • Stomach pain.
  • Dry mouth.
  • Muscle weakness or muscle pain.
  • Feeling of weakness.
  • Heaviness, tension, pain, or pressure in the throat, neck, arms, and legs, or chest.
  • Difficulty swallowing.

Uncommon side effects (may affect up to 1 in 100 people):

  • Very fast heartbeat.
  • Slightly higher blood pressure.
  • Increased amount of urine produced or increased number of times you need to urinate.

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Zolmitriptan Flas Cinfa

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of the month shown.

Do not store above 30°C.

Store in the original package.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Contents of the pack and other information

Composition of Zolmitriptan Flas Cinfa

  • The active substance is zolmitriptan. Each orodispersible tablet contains 2.5 mg of active substance.
  • The other ingredients are: mannitol (E-421), crospovidone, calcium silicate, aspartame (E-951), orange flavor, strawberry flavor, citric acid monohydrate (E-330), and magnesium stearate (E-470).

Appearance of Zolmitriptan Flas Cinfa and contents of the pack

Zolmitriptan Flas Cinfa orodispersible tablets are white or almost white, with flat faces, round, and with beveled edges.

They are presented in Alu/Alu blisters. Each pack contains 2, 6, or 12 (6x2) orodispersible tablets.

Not all pack sizes may be marketed.

Other presentations

Zolmitriptan Flas Cinfa 5 mg orodispersible tablets: packs of 2, 6, or 12 (6 x 2) tablets.

Marketing authorization holder and manufacturer

Marketing authorization holder

Laboratorios Cinfa, S.A.

Carretera Olaz-Chipi, 10. Polígono Industrial Areta

31620 Huarte (Navarra) - Spain

Manufacturer

Neuraxpharm Pharmaceuticals, S.L.

Avda. Barcelona 69

08970 Sant Joan Despí

Barcelona – Spain

or

Laboratorios Cinfa, S.A.

Carretera Olaz-Chipi, 10. Polígono Industrial Areta

31620 Huarte (Navarra) - Spain

Date of last revision of this leaflet:November 2020

Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/

You can access detailed and updated information about this medicine by scanning the QR code included in the leaflet and packaging with your smartphone. You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/74385/P_74385.html

QR code to: https://cima.aemps.es/cima/dochtml/p/74385/P_74385.html

Online doctors for ZOLMITRIPTAN FLAS CINFA 2.5 mg ORALLY DISINTEGRATING TABLETS

Discuss questions about ZOLMITRIPTAN FLAS CINFA 2.5 mg ORALLY DISINTEGRATING TABLETS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for ZOLMITRIPTAN FLAS CINFA 2.5 mg ORALLY DISINTEGRATING TABLETS?
ZOLMITRIPTAN FLAS CINFA 2.5 mg ORALLY DISINTEGRATING TABLETS requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in ZOLMITRIPTAN FLAS CINFA 2.5 mg ORALLY DISINTEGRATING TABLETS?
The active ingredient in ZOLMITRIPTAN FLAS CINFA 2.5 mg ORALLY DISINTEGRATING TABLETS is zolmitriptan. This information helps identify medicines with the same composition but different brand names.
How much does ZOLMITRIPTAN FLAS CINFA 2.5 mg ORALLY DISINTEGRATING TABLETS cost in pharmacies?
The average pharmacy price for ZOLMITRIPTAN FLAS CINFA 2.5 mg ORALLY DISINTEGRATING TABLETS is around 16.08 EUR. Prices may vary depending on the manufacturer and dosage form.
Who manufactures ZOLMITRIPTAN FLAS CINFA 2.5 mg ORALLY DISINTEGRATING TABLETS?
ZOLMITRIPTAN FLAS CINFA 2.5 mg ORALLY DISINTEGRATING TABLETS is manufactured by Laboratorios Cinfa S.A.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of ZOLMITRIPTAN FLAS CINFA 2.5 mg ORALLY DISINTEGRATING TABLETS online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether ZOLMITRIPTAN FLAS CINFA 2.5 mg ORALLY DISINTEGRATING TABLETS is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to ZOLMITRIPTAN FLAS CINFA 2.5 mg ORALLY DISINTEGRATING TABLETS?
Other medicines with the same active substance (zolmitriptan) include ZOLMITRIPTAN FLAS CINFA 5 mg ORALLY DISINTEGRATING TABLETS, ZOLMITRIPTAN FLAS COMBIX 2.5 mg ORALLY DISINTEGRATING TABLETS, ZOLMITRIPTAN FLAS QUALIGEN 2.5 mg ORALLY DISINTEGRATING TABLETS. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media